944547-46-0
944547-46-0 性质
| 密度 | 1.53±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | 二甲基亚砜：≥100mg/mL（189.80mM） |
| 酸度系数(pKa) | 6.95±0.46(Predicted) |
| 形态 | 固体 |
| 颜色 | 浅黄至黄色 |
| InChIKey | YPPNLSKYXDXQGD-UHFFFAOYSA-N |
| SMILES | N1(C2=CC=CC=C2)C(NC(C2C=C3N(N=2)C(C(Cl)(F)F)=CC(C2=CC=CO2)=N3)=O)=C(C(OCC)=O)C=N1 |
944547-46-0 用途与合成方法
Myc-MAX dimerization
Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). Mycro 3 has a superior specificity profile to its predecessors. Mycro 3 inhibits the interaction between c-Myc and Max. Mycro 3 has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA. Mycro 3 exhibits an excellent specificity with IC 50 s of 0.25 and 9.0 µM for cells with intact Myc alleles and Myc-null cells, respectively.
Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells.
| Animal Model: | Moribund Pdx1-cre/KRAS * mice bearing pancreatic ductal adenocarcinoma (PDA) |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; daily for two months |
| Result: |
Increased survival time.
Mycro 3 administration was discontinued after two months, the mouse survived for an additional month. |
944547-46-0 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-07-06 | S0249 | 944547-46-0 | 944547-46-0 | 5mg | 2970 |
| 2026-07-06 | S0249 | 944547-46-0 | 10mM (1mL in DMSO) | 3770 |
